Genflow Biosciences Share Discussion Threads

[moneymunch] 31/1/2024 22:38

Too many punters have sold their shares too cheaply, me thinks..
Gla holders...On and UP!!! :-)

[bri15] 31/1/2024 12:23

The Guardian financial section named Genflow as one of the firms to watch in 2024,well don't just watch, I'd advise you to get in before the crazy share price rise.

[logica2me] 31/1/2024 12:04

Looking good today this.

[bri15] 31/1/2024 11:55

Something is up for the ASK to be rising on sells.

[bri15] 31/1/2024 11:53

Massive rise coming here,so undervalued this one.

[moneymunch] 31/1/2024 11:22

On and UP!!! Gla holders:-)

[luckyabbeygale] 31/1/2024 11:17

1.9299p for £15,000 they now want.
Going by this my holding is now back in profit.

[moneymunch] 30/1/2024 12:49

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,457 followers

46m

2-5% of all Americans have NASH (Non-Alcoholic Steatohepatitis) - and these rates are rising. Understanding the disease and its treatment is vital to curtailing its impact on public health. Read more about the disease's rise and what is being done to treat it here:

#NASH #livertreatment #GenflowBiosciences #GENF #GENFF

[bri15] 30/1/2024 12:15

Off topic,Echo energy going to flying this afternoon.

[bri15] 30/1/2024 11:43

NT to buy and can sell all my holding straight off, something big coming, hopefully.

[bri15] 30/1/2024 11:22

Buys,buys and more buys, happy days returning hopefully 😁

[bri15] 30/1/2024 11:19

SP about to blow!

[moneymunch] 30/1/2024 11:02

An absolute steel at current low with potential significant news at anytime!!! Gla holders, Genflow is still set for a great year ahead imho. :-)

[northeast14] 29/1/2024 12:48

Yes absolutely ridiculous

[bri15] 29/1/2024 12:20

I really think we at bottom now,well I bloody hope so as I just put more in 😁

[bri15] 29/1/2024 12:14

Since the rise that is.

[bri15] 29/1/2024 12:09

N14 it's more than ridiculous when you think it's only about £20K total sells which have wiped about £1.3 million off the market cap.

[northeast14] 29/1/2024 11:53

Ridiculous seeing us back down here. Our cash in bank and grants money is bigger than mcap now.

[bri15] 29/1/2024 11:50

Nearly back to pre grant awards price,so very over sold territory now.

[bri15] 29/1/2024 11:32

Getting annoyed with the constant drop,I losing hefty chunk here now 😡

[moneymunch] 29/1/2024 07:04

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) chief executive officer Dr. Eric Leire spoke with Proactive's Stephen Gunnion to discuss the impact of two substantial research grants awarded to Genflow in Belgium.

These grants are not just financial boons but are fostering critical collaborations in the field of advanced therapy medicinal products (ATMPs), marking a new era in biotechnological research and development.

Stephen Gunnion (SG): Dr. Leire, can you elaborate on the scope of these grants and their importance for Genflow Biosciences?

Eric Leire (EL): These grants are a major milestone for us. They primarily focus on enhancing collaborations in advanced therapy medicinal products, or ATMPs. Specifically, they support our partnerships with EXO Biologics for exosome manufacturing and Revatis SA for sarcopenia research. Sarcopenia, the age-related muscle loss condition, is a critical research area for Genflow. The grants cover 80% of the project costs, which is substantial financial backing, allowing us to enhance our research capabilities significantly.

SG: Could you shed some light on how these collaborations align with Genflow’s broader strategic goals?

EL: Absolutely. These collaborations are integral to our three-year plan of building a robust biotech ecosystem in Belgium. By working closely with academic centres and various biotech actors, we aim to significantly bolster our research capabilities. This not only enhances our company valuation through meaningful milestones but also strengthens our position in the biotech market by increasing shareholder value and validating the scientific rigour of our research.

SG: With such a focused approach towards ATMPs and age-related diseases, what are the long-term implications for Genflow's research portfolio?

EL: Our long-term vision is to expand our pipeline, focusing on gene therapy and age-related diseases. This strategy is designed to mitigate financial and scientific risks in the challenging biotech market. By diversifying and strengthening our research portfolio, we aim to establish Genflow as a leader in biotech innovation, particularly in the field of longevity and age-related conditions.

SG: Finally, what are the future plans for Genflow in terms of collaborations and research directions?

EL: Looking ahead, we are actively seeking further collaborations to expand our pipeline. While we remain dedicated to gene therapy and tackling age-related diseases, our goal is to create a diversified research portfolio that can withstand market challenges. This approach is essential for sustainable growth and continued innovation in biotechnology.

[northeast14] 28/1/2024 20:52

Il be holding also till the end. Till the buyout!

[moneymunch] 28/1/2024 19:17

Always best to buy on the low and not sell on the low imho, but hope you do well wherever...Big news here could drop at anytime and I'll be holding Big for when it does...Tick Tock:-)

[kubera369] 28/1/2024 19:07

At the end of the day it's all about making money and with my experience here I rather gamble all in BiRD and if the share price here is still low as it is then all good Genflow is a winner but only when the FDA announce that Ageing is a disease and the NASH trials are still well over 12 months away.Cannot deal with the daily drip down of share price here We had no news since last year Aoril spike in share price until just recent and the share price again has dipped down It's crazy and I'm taking a calculated gamble and am certainly not going to get my wings clipped Good luck here and I may be back